Alumis (ALMS) Return on Sales (2025)

Alumis (ALMS) reported Return on Sales of 0.48% for Q4 2025, up 10.09% quarter-over-quarter from 0.54% in Q3 2025.

Alumis (ALMS) Return on Sales (2025) Analysis & Trends

Alumis (ALMS) has 1 years of Return on Sales data on file, last reported at 0.48% in Q4 2025.

  • Return on Sales for Q4 2025 came in at 0.48%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 0.1% (changed N/A YoY), and the FY2025 annual result was 0.1%, changed N/A from the prior year.
  • Return on Sales rose to 0.48% in Q4 2025 per ALMS's latest filing, from 0.54% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.22% in Q2 2025 and troughed at 0.54% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.00%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - 0.00%
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 0.00%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Alumis 1.99 Bn 1.90 Bn - -0.48%

Historic Data

Download Data
DateValue
Dec 31, 2025 -0.48%
Sep 30, 2025 -0.54%
Jun 30, 2025 0.22%
Mar 31, 2025 -0.06%